Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) EVP Sells 5,371 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Michael Erickson sold 5,371 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded down $4.17 during trading hours on Thursday, hitting $630.73. 307,461 shares of the company’s stock traded hands, compared to its average volume of 506,699. The stock has a market capitalization of $50.36 billion, a price-to-earnings ratio of 48.26, a PEG ratio of 3.81 and a beta of 1.67. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The company has a fifty day simple moving average of $680.64 and a 200-day simple moving average of $669.42.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on IDXX. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. UBS Group lowered their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Finally, Piper Sandler lowered their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

Institutional Investors Weigh In On IDEXX Laboratories

Several large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC raised its holdings in shares of IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IDEXX Laboratories in the second quarter worth approximately $265,000. Harbour Investments Inc. raised its stake in IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock valued at $53,000 after purchasing an additional 21 shares in the last quarter. Mutual Advisors LLC bought a new stake in IDEXX Laboratories during the second quarter valued at approximately $244,000. Finally, Nordea Investment Management AB grew its stake in IDEXX Laboratories by 4.7% in the 2nd quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock worth $4,298,000 after buying an additional 361 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.